Skip to main content
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MIST ISIN · USU6005B1045 LEI · 549300P43IPGW3Q3Y026 US Manufacturing
Open in API
Filings indexed 346 across all filing types
Latest filing 2020-01-24 Director's Dealing
Country US United States of America
Listing US MIST

About Milestone Pharmaceuticals Inc.

https://www.milestonepharma.com

Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company's lead investigational product is etripamil, a novel, fast-acting calcium channel blocker delivered as a nasal spray. This formulation is designed for patient self-administration to terminate episodes of certain heart rhythm disturbances outside of a hospital or emergency department setting. The primary indications under investigation for etripamil are paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), aiming to address unmet needs for acute, at-home treatment of these episodic conditions.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2020-01-24 English
4 Filing
Director's Dealing
2020-01-13 English
SC 13G Filing
Major Shareholding Notification
2020-01-09 English
4 Filing
Director's Dealing
2020-01-02 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 17, 2019, by Milestone Pharmaceuticals Inc. It announces an update to the company's corporate presentation used for conferences and meetings, and the presentation is filed as Exhibit 99.1. The document does not contain financial statements or detailed financial data but rather serves as a current report to inform about the updated corporate presentation. The length is 3483 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-12-17 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 29, 2019, for Milestone Pharmaceuticals Inc. The key content is the resignation of a board member, Marco Boorsma, from the Board of Directors and its committees. There is no financial data or report attached, and the document focuses solely on management/board changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 3493 characters, which is short and consistent with a typical 8-K announcement of management changes rather than a full report. Therefore, the correct classification is MANG with high confidence.
2019-12-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.